CORDIS
EU research results

CORDIS

English EN
REgenerative Stem cell therapy for STroke in Europe

REgenerative Stem cell therapy for STroke in Europe

Objective

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families.
Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life. RESSTORE European multicentre randomised phase IIb will explore, for the first time, the efficacy (functional recovery) and safety of intravenous infusion of allogenic adipose tissue derived mesenchymal stem cells (ADMSCs) in 400 stroke patients. Therapeutic effects of ADMSCs will be assessed and monitored in patients using clinical rating scales, multimodal MRI and novel blood biomarkers. Additionally, the societal value and cost-effectiveness of ADMSCs-based regenerative therapy will be evaluated through health economics and predictive in silico simulations. Complementary ancillary animal studies will support the clinical trial by defining i) if the treatment response can be further enhanced by intensive rehabilitation, ii) the contribution of co-morbidities and iii) the mechanism(s) underlying the therapeutic effect.
The European regenerative therapy capacities (France, Spain, Finland, United Kingdom and Czech Republic), developed in RESSTORE will cover the full value chain in the field (large scale GMP cell production, clinical testing, biomarkers discovery, understanding of the restoring mechanisms, modelling, biobanking, economic studies, exploitation and communication plan). RESSTORE will thus surely contribute, together with the workforce trained in the context of the programme, to improve its public and private (SME) competitiveness and increase the attractiveness of Europe as a reference location to develop and clinically assess new innovative therapeutic options for brain diseases.

Coordinator

UNIVERSITE GRENOBLE ALPES

Address

621, Avenue Centrale
38401 Saint Martin D'Heres

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 781 937,50

UNIVERSITE JOSEPH FOURIER GRENOBLE 1

Address

Avenue Centrale, Domaine Universitaire 621
38041 Grenoble

France

Activity type

Higher or Secondary Education Establishments

Participants (28)

Sort alphabetically

Sort by EU Contribution

Expand all

SERVICIO MADRILENO DE SALUD

Spain

EU Contribution

€ 134 600

CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE

France

EU Contribution

€ 182 700

FAKULTNI NEMOCNICE U SV. ANNY V BRNE

Czechia

EU Contribution

€ 20 000

SERVICIO ANDALUZ DE SALUD

Spain

EU Contribution

€ 446 825

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 20 000

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 185 035

ETABLISSEMENT FRANCAIS DU SANG

France

EU Contribution

€ 799 718

TAMPEREEN YLIOPISTO

Finland

EU Contribution

€ 360 791

HISTOCELL SL

Spain

EU Contribution

€ 327 365

OY MEDFILES LTD

Finland

EU Contribution

€ 802 187,50

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 130 325

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Spain

EU Contribution

€ 350 000

HOSPICES CIVILS DE LYON

France

EU Contribution

€ 70 000

ASSOCIATION GROUPE ESSEC

France

EU Contribution

€ 200 000

NOVADISCOVERY

France

EU Contribution

€ 274 375

FINOVATIS

France

EU Contribution

€ 232 000

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON

France

EU Contribution

€ 1 700

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 1 700

CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

France

EU Contribution

€ 1 700

CHU HOPITAUX DE BORDEAUX

France

EU Contribution

€ 1 700

CHU COTE DE NACRE - CAEN

France

EU Contribution

€ 1 700

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON

Spain

EU Contribution

€ 1 700

FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU

Spain

EU Contribution

€ 1 700

SERVICIO DE SALUD DE CASTILLA LA MANCHA

Spain

EU Contribution

€ 1 700

SERVIZO GALEGO DE SAUDE

Spain

EU Contribution

€ 1 700

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA DOCTOR JOSEP TRUETA

Spain

EU Contribution

€ 1 700

PIRKANMAA HOSPITAL DISTRICT

Finland

EU Contribution

€ 1 700

CENTRE HOSPITALIER SAINTE ANNE DE PARIS

France

EU Contribution

€ 1 700

Project information

Grant agreement ID: 681044

Status

Ongoing project

  • Start date

    1 September 2015

  • End date

    31 August 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 338 260

  • EU contribution

    € 6 338 259

Coordinated by:

UNIVERSITE GRENOBLE ALPES

France